Combination CAR-T Cell Therapy Targeting Hematological Malignancies
Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies
Shenzhen Geno-Immune Medical Institute
100 participants
Aug 1, 2025
INTERVENTIONAL
Conditions
Summary
The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Eligibility
Inclusion Criteria5
- age older than 6 months.
- malignant B cell surface expression of CD19/CD20/CD22/CD30/CD38/CD70/CD123 molecules.
- the KPS score over 80 points, and survival time is more than 1 month.
- greater than Hgb 80 g/L.
- no contraindications to blood cell collection.
Exclusion Criteria7
- accompanied with other active diseases, the treatment is difficult to assess patient response.
- bacteria, fungus, or virus infection, unable to control.
- living with HIV.
- active HBV and HCV infection.
- pregnant and nursing mothers.
- under systemic steroid treatment within a week of the treatment.
- prior failed CAR-T treatment.
Interventions
4SCAR19 and 4SCAR22
4SCAR19 and 4SCAR38
4SCAR19 and 4SCAR20
4SCAR19 and 4SCAR123
4SCAR19 and 4SCAR70
4SCAR19 and 4SCAR30
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03125577